Iksuda Therapeutics procures $47m

Iksuda Therapeutics, a developer of a new generation of antibody drug conjugates, has raised $47 million in funding.

7 June 2021•1 min read
Feature image
LinkedInXEmail
LinkedInXEmail

Related articles